Antimalarial therapy in SLE.
D000962:Antimalarials / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use*; D001665:Binding Sites / Q000187:drug effects; D002738:Chloroquine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D003316:Corneal Diseases / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006886:Hydroxychloroquine / Q000009:adverse effects / Q000378:metabolism / Q000627:therapeutic use; D007108:Immune Tolerance / Q000187:drug effects; D007249:Inflammation / Q000188:drug therapy; D007700:Kinetics; D008179:Lupus Erythematosus, Discoid / Q000188:drug therapy; D008180:Lupus Erythematosus, Systemic / Q000150:complications / Q000188:drug therapy*; D009698:Nucleoproteins / Q000378:metabolism; D010787:Photosensitivity Disorders / Q000188:drug therapy / Q000209:etiology; D011247:Pregnancy; D011796:Quinacrine / Q000627:therapeutic use; D012164:Retinal Diseases / Q000139:chemically induced; D012168:Retinal Pigments / Q000633:toxicity; D012871:Skin Diseases / Q000188:drug therapy / Q000209:etiology; D014779:Virus Replication / Q000187:drug effects
D000962:Antimalarials; D009698:Nucleoproteins; D012168:Retinal Pigments; D006886:Hydroxychloroquine; D002738:Chloroquine; D011796:Quinacrine